» Articles » PMID: 3237690

Pathology of the Lymph Node and Spleen in Systemic Mast Cell Disease

Overview
Journal Mod Pathol
Specialty Pathology
Date 1988 Jan 1
PMID 3237690
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The spleen and lymph node are two of the most common organs involved in systemic mast cell disease (SMCD). However, SMCD infiltrates in the spleen and lymph node have a broad spectrum of morphological patterns which can make it difficult to recognize the diagnosis, especially when specimens are examined from patients in whom SMCD is not suspected. We reviewed the pathological features of 16 spleen and 23 lymph node specimens from 19 patients which represented all available material from a series of 58 Mayo Clinic patients with SMCD. The purpose of this study was to investigate the pathological manifestations of SMCD involvement in the spleen and lymph node and to address difficulties in differential diagnosis. All compartments of the spleen and lymph node were found to be affected by SMCD. SMCD lesions in the spleen were found in a paratrabecular (92%), parafollicular (69%), follicular (15%), and a diffuse red pulp (8%) distribution. In the lymph node, mast cell infiltrates affected the paracortex (88%), the parafollicular region (50%), the follicles (25%), the medullary cords (13%), and the sinuses (6%). Mast cells were frequently found in a perivascular location, and associated eosinophilia was common. Because of the broad spectrum of histological manifestations of SMCD in the spleen and lymph node, a wide range of differential diagnoses is discussed including follicular lymphoma, T-cell lymphoma, monocytoid B-cell hyperplasia and lymphoma, Kaposi's sarcoma, and Langerhans' cell granulomatosis.

Citing Articles

Histopathology and Molecular Genetics in Systemic Mastocytosis: Implications for Clinical Management.

Crupi F, Sordi B, Vanderwert F, Gesullo F, Amorosi A, Mannelli F Int J Mol Sci. 2022; 23(15).

PMID: 35955907 PMC: 9369381. DOI: 10.3390/ijms23158772.


KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis.

Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L Leukemia. 2015; 29(6):1223-32.

PMID: 25650093 PMC: 4522520. DOI: 10.1038/leu.2015.24.


Mastocytosis.

Carter M, Metcalfe D, Komarow H Immunol Allergy Clin North Am. 2013; 34(1):181-96.

PMID: 24262698 PMC: 3863935. DOI: 10.1016/j.iac.2013.09.001.


Gastrointestinal manifestations of systemic mastocytosis.

Lee J, Whittaker S, Enns R, Zetler P World J Gastroenterol. 2008; 14(45):7005-8.

PMID: 19058339 PMC: 2773867. DOI: 10.3748/wjg.14.7005.


Regulation of normal and neoplastic human mast cell development in mastocytosis.

Metcalfe D Trans Am Clin Climatol Assoc. 2006; 116:185-203.

PMID: 16555614 PMC: 1473141.